AVDL AVADEL PHARMACEUTICALS PLC


$ 23.04 $ 0.09 (0.39 %)    

Friday, 21-Nov-2025 15:56:40 EST
QQQ $ 592.29 $ 0.00 (0 %)
DIA $ 462.33 $ 0.00 (0 %)
SPY $ 660.11 $ 0.00 (0 %)
TLT $ 89.82 $ 0.00 (0 %)
GLD $ 374.40 $ 0.00 (0 %)
$ na
$ 22.90
$ 22.60 x 4
$ 23.60 x 2,000
-- - --
$ 6.38 - $ 23.57
2,720,035
na
2.25B
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-equal-weight-on-avadel-pharmaceuticals-raises-price-target-to-225

Wells Fargo analyst Benjamin Burnett maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Equal-Weight and raises the price...

Core News & Articles

Lundbeck Proposal Values Avadel at up to $23.00 per Ordinary Share, a Total of Approximately $2.4 billionPursuant to Alkermes T...

 lundbecks-higher-buyout-proposal-challenges-alkermes-pending-2-billion-avadel-deal

Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whethe...

 wells-fargo-maintains-equal-weight-on-avadel-pharmaceuticals-raises-price-target-to-20

Wells Fargo analyst Benjamin Burnett maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Equal-Weight and raises the price...

 avadel-pharmaceuticals-q3-eps-000-misses-007-estimate-sales-77467m-beat-73574m-estimate

Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly earnings of $0.00 per share which missed the analyst consensus estimate...

 ubs-downgrades-avadel-pharmaceuticals-to-neutral-maintains-price-target-to-20

UBS analyst Ashwani Verma downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Buy to Neutral and maintains the price target...

 deal-dispatch-from-four-roses-bourbon-to-quantum-stakes-here-are-this-weeks-sector-shake-ups

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across va...

 leerink-partners-downgrades-avadel-pharmaceuticals-to-market-perform-announces-185-price-target

Leerink Partners analyst Marc Goodman downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Outperform to Market Perform and ...

 hc-wainwright--co-downgrades-avadel-pharmaceuticals-to-neutral-lowers-price-target-to-20

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Avadel Pharmaceuticals (NASDAQ:AVDL) from Buy to Neutral and l...

 alkermes-strikes-21-billion-avadel-deal-gains-access-to-narcolepsy-drug-lumryz

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION